Related references
Note: Only part of the references are listed.Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
Armando N. Bastidas Torres et al.
HAEMATOLOGICA (2022)
JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology
Megan J. Fitzpatrick et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)
Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Sharing the PCM1-JAK2 Fusion and a Common T-Cell Clone
Gregory M. Riedlinger et al.
JCO PRECISION ONCOLOGY (2019)
Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma
Ioannis Panagopoulos et al.
ONCOTARGET (2017)
Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma
Cristina Perez et al.
HAEMATOLOGICA (2015)
Genomic landscape of cutaneous T cell lymphoma
Jaehyuk Choi et al.
NATURE GENETICS (2015)
Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma
Cristina Perez et al.
HAEMATOLOGICA (2015)
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements
Andrew Chase et al.
HAEMATOLOGICA (2013)
t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5
Stefan Ehrentraut et al.
PLOS ONE (2013)
Modeling ETV6-JAK2-induced leukemia: insights from the zebrafish
Jurg Schwaller
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
Katrien Van Roosbroeck et al.
BLOOD (2011)
Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia
Jennifer L. Poitras et al.
GENES CHROMOSOMES & CANCER (2008)
Share Paper
